Vaccines are designed to guard babies, toddlers, and older children against a whole range of serious and potentially deadly ...

Moderna's study looked at the vaccine in adults aged 50 and older, while Pfizer/BioNTech's trial focused on adults aged 18 to 64. Other rivals, meanwhile, include Sanofi/Novavax, which are ...

According to Pfizer and BioNTech, this is the first time that an mRNA-based flu vaccine has started a phase 3 efficacy trial. Its rival Moderna said earlier this month, however, that it has ...

Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of $2.69. In the year-ago period, the company had reported earnings ...

A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...

Pfizer’s contributions to animal health date back several decades, during which the company played a significant role in ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Robert F Kennedy Jr was confirmed as US Secretary of Health and Human Services in a 52-48 Senate vote. The vaccine skeptic will oversee agencies like the FDA, CDC, and NIH. His ‘Make America Healthy ...

The discovery has shed light on a complex blood interaction that has likely always been present in humans but was unnoticed ...

The World Health Organization wants to tackle inequity and bureaucracy relating to clinical trials. Will its latest guidance make a difference? Anna Volkmer reports During the covid-19 pandemic the UK ...

Texas Attorney General Ken Paxton has launched an investigation into DeepSeek, the upstart Chinese artificial intelligence ...

While sales of its COVID vaccine, Comirnaty, declined by 52% to $5.4 billion for the full year, the company's top line still rose by 7%. Pfizer's specialty care segment generated 11% growth ...